Expanded Access to ABBV-787
Latest Information Update: 07 Apr 2025
At a glance
- Drugs ABBV-787 (Primary)
- Indications Acute myeloid leukaemia
- Focus Expanded access; Therapeutic Use
- Sponsors AbbVie
Most Recent Events
- 06 Jun 2024 New trial record
Latest Information Update: 07 Apr 2025